The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Spinal Cord Injury Research Program (SCIRP) -- Investigator-Initiated Research Award
The SCIRP IIRA is intended to support studies that have the potential to make an important contribution to SCI research, patient care, and/or quality of life.
Important aspects of this award mechanism include:
• Impact: Applications should articulate the short- and long-term impact of the proposed research on both the SCI research field as well as the SCI community. Projects must address one or more of the FY22 SCIRP Focus Areas.
• Relevance to Military Health: Projects should be relevant to spinal cord-injured military Service Members, Veterans, and/or their family members and care partners. Collaboration with military and VA researchers and clinicians is encouraged.
• Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the SCIRP and support the proposed research project.
IIRA applications may focus on any phase of research from basic through translational, though studies focused exclusively on target identification are discouraged. Permitted research includes preclinical studies in animal models (except where otherwise specified), research with human subjects, or human anatomical substances, as well as ancillary studies associated with an existing clinical trial.
- Pre-Application Deadline: May 23, 2022
- Invitation to Submit an Application: July 2022
- Application Submission Deadline: Sep. 2, 2022
Areas of Interest
Applications to the FY22 SCIRP Investigator-Initiated Research Award (IIRA) must address at least one of the Focus Areas listed below. Applications may address more than one Focus Area. In particular, applications combining biomarker studies with studies in one or more of the other Focus Areas are encouraged. Applications using clinically relevant combinations of interventions within or across Focus Areas are also encouraged. The FY22 SCIRP Focus Areas are:
• Preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes ○ Responsive projects may include surgical and acute care management of SCI. ○ Therapeutics (devices and pharmacologic interventions) to stabilize SCI in the prehospital environment and during transport are encouraged. ○ Applications proposing neuroprotective interventions need to demonstrate a clinically feasible window for treatment and more than an incremental improvement over existing therapies.
• Identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies ○ Biomarkers must focus on diagnosis, prognosis, progression, and/or recovery of SCI. ○ Projects with a clear link between a biomarker and underlying physiology are encouraged. Projects can include imaging and other modalities. ○ Applications should demonstrate a clear path to clinical use. ○ Biomarker studies directed at identifying the best single or combination of treatments for individuals (personalized medicine) are encouraged.
• Developing, testing, and validating promising interventions to address bowel, genitourinary, neuropathic pain, cardiopulmonary, or autonomic dysfunction in people with SCI ○ Mechanism-focused studies must be specific to SCI and demonstrate a clear path from increased understanding to advancing treatments. ○ Studies addressing the needs of and treatments for individuals with SCI across the full lifespan from acute to chronic injury are encouraged.
• Investigating psychosocial issues relevant to people with SCI, their families, and/or their care-partners ○ Applications should directly address, or show clear relevance to, the needs of Service Members and Veterans. ○ To be responsive to this Focus Area, psychosocial issues must be the primary focus of the research. ○ Projects should provide an understanding of critical factors promoting psychosocial well-being leading to implementation of potential treatments and interventions. ○ Studies addressing social isolation, loneliness, and depression, as well as resilience, selfefficacy, sexuality and intimacy, and interactions between people living with SCI and their care-partners, are especially encouraged. ○ Preclinical animal studies are not responsive to this Focus Area.
• Rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after SCI ○ Studies that address critical questions of dosing, targeting, or safety required to move the research toward clinical use are supported. ○ Applications studying mechanisms of regeneration or identifying novel therapeutic targets must include a feasible projected pathway for translation and clinical implementation. ○ Basic research projects designed to understand general mechanisms underlying axonal sprouting, regeneration, or neuroplasticity are discouraged unless they directly address translatable approaches.
Independent investigators at all academic levels (or equivalent) may be named by the organization as the PI on the application.
The Partnering PI must be an independent, early-career investigator within 10 years after completion of their terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application.
The anticipated direct costs budgeted for the entire period of performance for an FY22 SCIRP Investigator-Initiated Research Award will not exceed $500,000 or $600,000 for the EarlyCareer Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.